In a recent statement, Plandai Biotechnology Inc (OTCMKTS:PLPL) mentioned about its strategic deal with USN. According to reports, Ultimate Sports Nutrition would use Phytofare in the development of a new range of products to be sold in New Zealand and Australia market.
Plandai and USN signed an agreement in the past, under which the latter had to use Phytofare in all the green tea products being manufactured or sold in Europe or South Africa. As the competition in the market is climbing day by day, both the companies have now decided to take their existing relation to newer heights.
According to reports, USN will now contact different manufacturers in its vendor list and convince them to sell Phytofare in different markets, starting from New Zealand and Australia. By this way, both the companies want to ensure if the current agreement between them is good enough to continue in the future as well.
Plandai Biotechnology is also trying to grab the market share in new countries with the help of a huge network of USN. The management teams of USN and Plandai Biotechnology are excited to revamp this commercial relation and hope that this will turn out to be one of the best steps taken by both the companies in the recent past.
Another leading company named Metabolix, Inc. (NASDAQ:MBLX) has announced financial results for the second quarter ending June 30, 2015. The company managed to maintain a reasonably good cash position throughout the quarter, which helped it closing 2Q2015 with $22.7 million unrestricted cash in hand. However, strong cash position couldn’t help it much as Metabolix ended the quarter with $6.1 million loss against last year’s $6.8 million loss.
Meanwhile, a renowned botanical therapeutics company Herborium Group, Inc. (OTCMKTS:HBRM) has decided to launch a series of new websites focusing on the promotion and advertisement of its premier product AcnEase. As per the reports, AcnEase is widely used for the treatment of life-threatening diseases rosacea and acne.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: